DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Study to Evaluate the Bioequivalence of Pfizer Korea Inc. "XELJANZ 5Mg Tablet" in Healthy Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: XELJANZ 5Mg Tablet
Drug: Chong Kun Dang Tofacitinib Tablet

First Posted Date: 2019-03-08

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT03868072

Locations: 🇰🇷
Bestian Hospital, Osong, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: D569 Tab.
Drug: CKD-374 5mg Tab.

First Posted Date: 2019-03-01

Last Posted Date: 2020-01-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03858725

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed Condition

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-387
Drug: D635

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 20

Registration Number: NCT03849339

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults

Phase 1

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: CKD-333, formula I
Drug: CKD-333, formula II
Drug: CKD-330, D090

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03849287

Locations: 🇰🇷
Seoul Saint Mary's Hospital, Seoul, Korea, Republic of

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy Adults

Phase 1

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: CKD-387
Drug: D635

First Posted Date: 2019-02-21

Last Posted Date: 2019-02-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03849261

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-375

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-375
Drug: D387

First Posted Date: 2019-02-21

Last Posted Date: 2019-03-06

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT03848637

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-370 and D745 in Healthy Adults

Phase 1

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-370
Drug: D745

First Posted Date: 2019-02-21

Last Posted Date: 2019-03-12

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 28

Registration Number: NCT03849495

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355

Phase 1

Completed

Conditions: Alzheimer's Disease (AD)

Interventions: Drug: CKD-355A (D797/Memantine HCl 20mg)
Drug: CKD-355B (D797/Memantine HCl 20mg)
Drug: D797
Drug: D324 (Memantine HCl 10mg)

First Posted Date: 2019-01-14

Last Posted Date: 2019-10-23

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 60

Registration Number: NCT03802162

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome

Phase 4

Completed

Conditions: Kidney Transplant

Interventions: Drug: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
Drug: Tacrolimus
Drug: Methylprednisolone/prednisolone
Drug: Basiliximab

First Posted Date: 2019-01-07

Last Posted Date: 2024-05-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 169

Registration Number: NCT03794492

Locations: 🇰🇷
Ajou University Hospital, Suwan, Korea, Republic of

Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337

Phase 1

Completed

Conditions: Hyperlipidemias

Interventions: Drug: T
Drug: R

First Posted Date: 2019-01-04

Last Posted Date: 2019-01-07

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 45

Registration Number: NCT03793985

Locations: 🇰🇷
INHA University Hospital, Incheon, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy